Tetraphase Pharms Drug Patent Portfolio
Tetraphase Pharms owns 1 orange book drug protected by 4 US patents Given below is the list of Tetraphase Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10961190 | Crystalline forms of eravacycline | 19 Oct, 2037 | Active |
| US11578044 | Crystalline forms of eravacycline | 19 Oct, 2037 | Active |
| US8906887 | C7-fluoro substituted tetracycline compounds | 28 Dec, 2030 | Active |
| US8796245 | C7-fluoro substituted tetracycline compounds | 07 Aug, 2029 | Active |
Latest Legal Activities on Tetraphase Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tetraphase Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8906887 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8906887 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Feb, 2023 | US11578044 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Feb, 2023 | US11578044 |
|
Email Notification
Critical
| 26 Jan, 2023 | US11578044 |
|
Issue Notification Mailed
Critical
| 25 Jan, 2023 | US11578044 |
| Dispatch to FDC | 09 Jan, 2023 | US11578044 |
|
Application Is Considered Ready for Issue
Critical
| 09 Jan, 2023 | US11578044 |
| Supplemental Papers - Oath or Declaration | 05 Jan, 2023 | US11578044 |
|
Issue Fee Payment Received
Critical
| 05 Jan, 2023 | US11578044 |
|
Issue Fee Payment Verified
Critical
| 05 Jan, 2023 | US11578044 |
|
Mail Notice of Allowance
Critical
| 06 Oct, 2022 | US11578044 |
|
Email Notification
Critical
| 06 Oct, 2022 | US11578044 |
|
Electronic Review
Critical
| 06 Oct, 2022 | US11578044 |
|
Notice of Allowance Data Verification Completed
Critical
| 03 Oct, 2022 | US11578044 |
Tetraphase Pharms Drug Patents' Oppositions Filed in EPO
Tetraphase Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 18, 2018, by Sandoz Ag. This opposition was filed on patent number EP15180611A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15180611A | Jul, 2018 | Sandoz AG | Revoked |
Tetraphase Pharms's Family Patents
Tetraphase Pharms Drug List
Given below is the complete list of Tetraphase Pharms's drugs and the patents protecting them.
1. Xerava
Xerava is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10961190 | Crystalline forms of eravacycline |
19 Oct, 2037
(12 years from now)
| Active |
| US11578044 | Crystalline forms of eravacycline |
19 Oct, 2037
(12 years from now)
| Active |
| US8906887 | C7-fluoro substituted tetracycline compounds |
28 Dec, 2030
(5 years from now)
| Active |
| US8796245 | C7-fluoro substituted tetracycline compounds |
07 Aug, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xerava's drug page